Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 24 for:    stargardt's macular dystrophy
Previous Study | Return to List | Next Study

Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Institute for Regenerative Medicine )
ClinicalTrials.gov Identifier:
NCT01345006
First received: April 28, 2011
Last updated: August 9, 2016
Last verified: August 2016